Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Apr 10;70(8):1691-1694.
doi: 10.1093/cid/ciz488.

Cryptococcal Antigen Screening and Preemptive Treatment-How Can We Improve Survival?

Radha Rajasingham  1 , David R Boulware  1
Affiliations
Comment

Cryptococcal Antigen Screening and Preemptive Treatment-How Can We Improve Survival?

Radha Rajasingham et al. Clin Infect Dis. .
No abstract available

Keywords: AIDS; Cryptococcus; HIV; cryptococcal meningitis; screening.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Plasma CrAg titer association with CSF CrAg status among 133 persons identified via CrAg screening programs in Ethiopia, South Africa, Tanzania, and Uganda. The prevalence of CSF CrAg positivity increases with both plasma CrAg titer as well as the presence of headache. Abbreviations: CrAg, cryptococcal antigen; CSF, cerebrospinal fluid; neg, negative; pos, positive.
Figure 2.
Figure 2.
Survival in CrAg-positive persons by plasma CrAg titer. Among asymptomatic persons in whom CSF CrAg positivity was excluded, similar outcomes occurred among those with a CrAg titer ≤1:320 regardless of symptoms (P = .68). CNS symptoms most dramatically decreased survival among those with plasma CrAg titers of 1:160 to 1:320, frequently associated with a positive CSF CrAg. Poor survival occurred among persons with plasma CrAG titers >1:640, regardless of symptoms. Neither symptoms nor CSF CrAg status predicted CNS dissemination in this group with high plasma titers. Abbreviation: CrAg, cryptococcal antigen.
See this image and copyright information in PMC

Comment on

References

    1. Meya DB, Manabe YC, Castelnuovo B, et al. . Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or =100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 2010; 51:448–55. - PMC - PubMed
    1. Letang E, Muller MC, Ntamatungiro AJ, et al. . Cryptococcal antigenemia in immunocompromised human immunodeficiency virus patients in rural tanzania: a preventable cause of early mortality. Open Forum Infect Dis 2015; 2:ofv046. - PMC - PubMed
    1. Rajasingham R, Smith RM, Park BJ, et al. . Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis 2017; 17:873–81. - PMC - PubMed
    1. World Health Organization. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children Available at: http://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en/. Accessed 1 April 2018. - PubMed
    1. Tugume L, Rhein J, Hullsiek KH, et al. ; COAT and ASTRO-CM Teams HIV-associated cryptococcal meningitis occurring at relatively higher CD4 counts. J Infect Dis 2019; 219:877–83. - PMC - PubMed

Publication types